VANDA PHARMACEUTICALS INC.: 10-Q filed 2015-05-07
What VANDA PHARMACEUTICALS INC. reported in its quarterly report filed 2015-05-07 (fiscal Q1 2015): 30 published measures, 62 facts as tagged in accession 0001193125-15-177216.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-05-07
- Fiscal period
- fiscal Q1 2015
- Accession
- 0001193125-15-177216 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VANDA PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 213,640,000 | USD | |
| At 2014-12-31 | 171,704,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 61,167,000 | USD | |
| At 2014-12-31 | 10,887,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 152,473,000 | USD | |
| At 2014-12-31 | 160,817,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 32,809,000 | USD | |
| At 2014-12-31 | 60,901,000 | USD | |
| At 2014-03-31 | 43,260,000 | USD | |
| At 2013-12-31 | 64,764,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -10,221,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -26,533,000 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 783,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 135,000 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 22,150,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 9,143,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | -298,205,000 | USD | |
| At 2014-12-31 | -287,984,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 3,080,000 | USD | |
| At 2014-12-31 | 2,437,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 1,945,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 1,393,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -10,293,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -26,578,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 162,167,000 | USD | |
| At 2014-12-31 | 141,730,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 31,789,000 | USD | |
| At 2014-12-31 | 7,786,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 1,490,000 | USD | |
| At 2014-12-31 | 835,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 47,580,000 | USD | |
| At 2014-12-31 | 26,724,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 20,120,000 | USD | |
| At 2014-12-31 | 3,654,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 5,215,000 | USD | |
| At 2014-12-31 | 5,170,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 18,806,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 27,893,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 4,478,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 7,263,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 41,793,422 | shares | |
| At 2014-12-31 | 41,486,361 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 27,000 | USD | |
| At 2014-12-31 | 16,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 4,378,000 | USD | |
| At 2014-12-31 | 3,101,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 30,299,000 | USD | |
| At 2014-12-31 | 6,951,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 2,503,000 | USD | |
| At 2014-12-31 | 3,084,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -10,210,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -26,546,000 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 140,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 125,000 | USD | 90 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 4,144,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 565,000 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 16,466,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -340,000 | USD | 90 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 45,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 192,000 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 654,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 292,000 | USD | 90 |
Inspect the source
- Entity
- VANDA PHARMACEUTICALS INC. / CIK 0001347178
- Captured
- 2026-09-20T07:54:54.067Z
- SEC response SHA-256
73fc153c337a0fde6ea6f321d6378d9f94925087244e6f7cab0e2262e4e90436
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001347178.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))